paf

PAF (C16) is a potent MAPK and MEK ERK activator that induces increased vascular permeability. PAF (C16) (PAF (C16)) is a platelet-activating factor, a phospholipid-derived mediator and a ligand for PAF G protein-coupled receptor (PAFR). PAF (C16) has shown anti-apoptotic and anti-inflammatory activity in vitro, inhibiting Caspase-dependent apoptosis by interacting with its receptor (PAF-R) to perform cell signaling.

PAF-AN-1 is a novel potent platelet-activating factor receptor (PAF) antagonist involved in the study of anaphylactic death.

PAF C-18 is a naturally occurring phospholipid molecule belonging to the platelet-activating factor (PAF) family, which acts as an intercellular signaling molecule involved in platelet aggregation, vasodilatation, and inflammatory responses.PAF C-18 is involved in hemostasis and thrombosis by binding to its specific G-protein-coupled receptor (PAFR) and activating.

Lyso-PAF C-16 is a biologically inactive precursor of platelet-activating factor (PAF).

2-O-Ethyl PAF C-16, a homolog of Platelet-activating Factor (PAF) and competitive ligand for the Platelet-activating Factor Receptor (PAFR), inhibits the binding of PAF antagonist WEB 2086 to PAFR with an IC50 of 21 nM [1].

Methylcarbamyl PAF C-16 (Carbamyl-PAF) is a platelet-activating factor analogue with PAF agonist properties, activating inflammation in pregnancy tissues and promoting preterm birth.

PAF C-18:1 is a naturally occurring phospholipid produced by cells upon stimulation and plays a role in the establishment and maintenance of the inflammatory response. It is less potent than PAF C-16 and PAF C-18 in the induction of neutrophil chemotaxis, but is equipotent to PAF C-16 and PAF C-18 in promoting eosinophil migration. PAF C-18:1 activates the PAF receptor and has been used in antibody binding experiments to determine the importance of an acyl linkage at the sn-2 position for recognition at this receptor.

PAF C-16 is a naturally occurring phospholipid produced upon stimulation through two distinct pathways known as the remodeling and 'de novo' pathways. It is a potent mediator of neutrophil migration and the production of reactive oxygen species and IL-6. Pathological processes involving PAF include necrotizing enterocolitis

Oxidized low-density lipoprotein (oxLDL) encompasses low molecular weight entities that facilitate monocyte differentiation and activate polymorphonuclear leukocytes. A substance, recently isolated and purified from oxLDL and identified as azelaoyl PC, exemplifies this. Similarly, Butanoyl PAF, a compound closely related to azelaoyl PC, maintains over 10% of the agonist potency of platelet-activating factor (PAF). Notably, Butanoyl PAF's concentration in oxLDL surpasses that of enzymatically generated PAF by more than 100-fold, making it a significant signalling molecule within oxLDL.

2-Thio-PAF is a synthetic analog of PAF used in a colorimetric assay for PAF acetylhydrolase.

Azelaoyl PAF is a potent PPARγ agonist that competitively binds thiazolidinediones with potency comparable to rosiglitazone. In atherosclerosis studies, Azelaoyl PAF promotes the uptake of oxidized low-density lipoprotein (oxLDL) by macrophages by upregulating CD36 expression. In fibroblasts from Friedreich's ataxia (FRDA) patients, Azelaoyl PAF significantly increased mRNA and protein levels of ferritin.

2-O-methyl PAF C-16 is a synthetic analog of platelet-activating factor (PAF) featuring a methyl group attached via an ether linkage at the sn-2 position. While the specific biological activities of 2-O-methyl PAF C-16 remain undercharacterized, studies with its C-18 counterpart have demonstrated its ability to modulate various biological processes. These processes include reducing plasma membrane fluidity and hindering the invasiveness of tumor cells in embryonic chick hearts. Furthermore, in rat astrocytes, the C-18 analog prompts the release of significant amounts of nitric oxide (NO) through a mechanism that involves the activation of nitric oxide synthase (NOS).

Rocepafant (LAU8080) is a platelet-activating factor (PAF) antagonist that attenuates hypoxic-ischemic brain damage in neonatal rats.Rocepafant inhibits tumor necrosis factor-Afa-mediated cytotoxicity in mouse L929 tumor cells.

Tulopafant (RP 59227) is a potent platelet-activating factor (PAF) antagonist that increases capillary patency and prolongs allograft heart survival.

(Rac)-Modipafantis an orally available and selective platelet-activating factor receptor (PAFR) antagonist that inhibits PAF-induced aggregation of washed platelets in rabbits, and can be used to study arthritis and ischemia reperfusion (I R) in the superior mesenteric artery (SMA) of the rat.

Pafenolol is a P-glycoprotein modulator with a Ki value of 5.5 µM. pafenolol is an orally available and selective beta-adrenergic receptor antagonist.

Propafenone (Propafenonum) is only found in individuals that have used or taken this drug. It is an antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.

Nepafenac (AHR 9434) is a Nonsteroidal Anti-inflammatory Drug. The mechanism of action of nepafenac is as a Cyclooxygenase Inhibitor. The chemical classification of nepafenac is Nonsteroidal Anti-inflammatory Compounds.

Foropafant (SR27417) is a highly potent and selective platelet-activating factor (PAF) receptor antagonist (Ki: 57 pM). Foropafant potently inhibits the PAF-induced aggregation of rabbit and human platelets.

Lexipafant is a platelet-activating factor (PAF) receptor antagonist which inhibits the binding of PAF to its receptor, thereby reducing inflammation and associated tissue injury. [Reduce organ damage, mitigate sepsis].

Setipafant is an antagonist of the platelet-activating factor.

Bepafant is a platelet activating factor (PAF) antagonist. Bepafant may produce significant anti-inflammatory effects. Bepafant triggered apoptosis in NB4, KG1, and NB4-MR4 cells where PTEN was expressed, but not in THP1 and U937 cells where PTEN was abse

Modipaafant is a potent dihydropyridine PAF (platelet activating factor) antagonist.

Israpafant is a selective antagonist for the platelet-activating factor receptor ( IC50 = 0.84nM). Israpafant inhibits PAF-induced human platelet aggregation. Israpafant inhibits the activation of eosinophil cells and consequently delays the development o